Cargando…

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

Patients with metastatic or recurrent and refractory sarcomas have a dismal prognosis. Therefore, new targeted therapies are urgently needed. This study was designed to evaluate chimeric antigen receptor (CAR) T cells targeting the type I insulin-like growth factor receptor (IGF1R) or tyrosine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xin, Park, Haein, Greene, Joseph, Pao, James, Mulvey, Erin, Zhou, Sophia X., Albert, Catherine M., Moy, Fred, Sachdev, Deepali, Yee, Douglas, Rader, Christoph, Hamby, Carl V., Loeb, David M., Cairo, Mitchell S., Zhou, Xianzheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501840/ https://www.ncbi.nlm.nih.gov/pubmed/26173023 http://dx.doi.org/10.1371/journal.pone.0133152

Ejemplares similares

Anti-ROR1 CAR-T cells: Architecture and performance
por: Osorio-Rodríguez, Daniel Andrés, et al.
Publicado: (2023)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies
por: Lee, Boon kiat, et al.
Publicado: (2022)

ROR1 and ROR2 expression in pancreatic cancer
por: Liu, Dongli, et al.
Publicado: (2021)

THU543 Acquired Resistance To CDK4/6 Inhibitors Is Associated With Upregulated IGF1R And IR Signaling
por: Gerhardt, Summer Louise, et al.
Publicado: (2023)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
por: Rebagay, Guilly, et al.
Publicado: (2012)

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2021)

Evolutionary Divergence in the Catalytic Activity of the CAM-1, ROR1 and ROR2 Kinase Domains
por: Bainbridge, Travis W., et al.
Publicado: (2014)

New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome
por: Raivola, Juuli, et al.
Publicado: (2022)

Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
por: Harrasser, Micaela, et al.
Publicado: (2022)

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1
por: John, Miya, et al.
Publicado: (2022)

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C E, et al.
Publicado: (2016)

IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
por: Lin, Weiwei, et al.
Publicado: (2023)

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
por: Yang, Jiahui, et al.
Publicado: (2011)

ROR1: an orphan becomes apparent
por: Kipps, Thomas J.
Publicado: (2022)

Construction and Stable Expression of a Truncated Human Receptor Tyrosine Kinase Ror1 (Ror1-ECD)
por: Forouzesh, Flora, et al.
Publicado: (2012)

High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
por: Ghia, Emanuela M., et al.
Publicado: (2022)

Assessing the Selectivity of FXR, LXRs, CAR, and RORγ Pharmaceutical Ligands With Reporter Cell Lines
por: Toporova, Lucia, et al.
Publicado: (2020)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
por: Henry, C. E., et al.
Publicado: (2022)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis
por: Henry, Claire, et al.
Publicado: (2017)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity
por: Ou, Zhenglin, et al.
Publicado: (2022)

IGF1R immunohistochemistry in Ewing’s sarcoma as predictor of response to targeted therapy
por: Gonzalez, Elizabeth, et al.
Publicado: (2020)

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
por: Stüber, Tanja, et al.
Publicado: (2020)

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer()
por: Henry, CE, et al.
Publicado: (2017)

ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma
por: Zheng, Yu-Zhu, et al.
Publicado: (2016)

Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
por: Hojjat-Farsangi, Mohammad, et al.
Publicado: (2013)

α CAR IGF‐1 vector targeting of motor neurons ameliorates disease progression in ALS mice
por: Eleftheriadou, Ioanna, et al.
Publicado: (2016)

Correction: Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Publicado: (2020)

Functional and clinical significance of ROR1 in lung adenocarcinoma
por: Giovanna, Schiavone, et al.
Publicado: (2020)

The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
por: Tzanakakis, George N., et al.
Publicado: (2021)

Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target
por: Herrero-Martín, D, et al.
Publicado: (2009)

IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis
por: Martins, Ana Sofia, et al.
Publicado: (2011)

Retraction: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells
Publicado: (2022)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1(+) CLL cells
por: Ghaderi, Amineh, et al.
Publicado: (2021)

Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy
por: de Groot, Stefanie, et al.
Publicado: (2017)

ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer
por: Zhou, Jian-Kang, et al.
Publicado: (2017)

Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells
por: Wu, Xuping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gbpnu21a7sl5vepol98apiti8s